INTROGEN THERAPEUTICS INC

Form 4 June 01, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * GILLIS STEPHEN MALCOLM			2. Issuer Name and Ticker or Trading Symbol INTROGEN THERAPEUTICS INC [INGN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) 2250 HOLO	(First) (I	Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/30/2007			_X Director Officer (give below)		Owner er (specify		
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting		
(City)		(Zip)	Takl	a I. Nam F	\ ! 4 !	C	.: A	Person	ć D	l O d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	•	ned Date, if	3. Transactic Code (Instr. 8)	4. Securit	ties A	equired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
common stock	05/30/2007(1)			A	7,919	A	0.001	15,419	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
stock option (3)	\$ 4.42	05/30/2007		A	37,000	<u>(4)</u>	05/29/2017	common stock	37,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
• 0	Director	10% Owner	Officer	Other		
GILLIS STEPHEN MALCOLM 2250 HOLCOMBE BLVD HOUSTON, TX 77030	X					

Signatures

/s/ Rodney Varner, by power of attorney 05/31/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted shares of common stock shall be granted and issued on the date that Reporting Person enters into the Companys form of stock purchase agreement with the Company.
- The purchase price for the shares has been paid by the Reporting Person via services previously rendered to the Company. The \$.001 represents the par value per share.
- (3) Right to buy.
- (4) This option vests in 12 equal monthly installments beginning on May 30, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2